DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
A hormetic transcriptional program coregulates invasion, proliferation and dormancy to define metastatic potential
Metastasis remains the leading cause of cancer mortality, yet the factors that determine metastatic competence and the timing of its acquisition are not well understood. Using human breast cancer cohorts and multi-omics in preclinical models, here we show that cells exit the primary tumor with pre-set metastatic potential. Integrating spatial transcriptomics with single-cell gene expression and chromatin profiles, we identify the transcription factor Prrx1 as a master regulator of dissemination: beyond its known role in invasion, it represses proliferation by acting on cyclins and cell-cycle inhibitors (Ccnd1/2, Cdkn2a/b/c) and activates a dormancy program (Gas6, Mme, Ogn). Intermediate Prrx1 levels optimize the trade-off between invasion and proliferation/dormancy, producing a hormetic (nonlinear) relationship between Prrx1 expression and metastatic burden. Combined invasion and proliferation signatures strongly stratify breast cancer prognosis, underscoring the clinical relevance of this phenotypic interplay. These findings indicate that metastatic competence emerges from the integration of Prrx1 co-regulated molecular programs, explaining why some invasive cells enter dormancy while others resume growth., The authors thank S. Vega for help and support in managing cell lines and T. M. Gomez, C. López-Blau, and G. Osuna for technical support, and G. Expósito and V. Villar for support at the imaging facility. The authors also thank A. Caler and Pep Mulet for technical help in the FACS/Omics facility. The authors thank Holger Heyn´s team at CNAG (National Center for Genomic Analysis, Barcelona, Spain), especially Sergio Aguilar, Laura Jiménez, and Helena Crowell, for suggestions on scRNA-seq analysis. The authors thank the MD Anderson Foundation Biobank for providing samples (record number B.0000745, Instituto de Salud Carlos III National Biobank). This work was supported by grants MCI PID2021-125682NB-I00 and PID2024-155973NB-I00 to M.A.N., and PID2022-136854OB-I00 to G.M.-B., all funded by MICIU/AEI/10.13039/501100011033 and by FEDER; UE. Funds were also provided by the AECC Scientific Foundation (FC_AECC PRYGN25NIET) and Generalitat Valenciana (Prometeo 2021/45) to M.A.N., and Instituto de Salud Carlos III (CIBERONC, CB16/12/00295) to G.M.-B. M.A.N. also acknowledges financial support from Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033, and support from the Scientific Network Conexión Cáncer funded by CSIC, Spain. K.K.Y. held an investigator contract from the AECC Scientific Foundation (Ayudas AECC investigador 2022). N.N. is hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds, and R.J.-C. holds a “Severo Ochoa Excellence Programme” PhD contract (PRE2020-091888)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-125682NB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2024-155973NB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136854OB-I00
,
AEI CEX2021-001165-S